Denali Therapeutics Inc. (NASDAQ:DNLI) did not report any operating expenses for Q3 2024 in the available data1. However, the company's financial performance and strategic developments can be analyzed from related reports:
- Revenue Decline: The company reported revenue of $1.00 million for Q3 2024, which was significantly lower than the analyst expectations of $10.00 million23. This substantial revenue shortfall might indicate a reduction in operating expenses as a result of cost control measures.
- Financial Performance: Denali Therapeutics reported an earnings per share (EPS) of ($0.59) for the quarter, which beat analysts' consensus estimates of ($0.68) by $0.0923. This suggests that despite the revenue shortfall, the company managed to improve profitability by reducing expenses.
In conclusion, the drop in Denali Therapeutics' operating expenses in Q3 2024 can be attributed to a combination of factors including cost control measures and reduced expenses despite a significant revenue decline.
5/9/2025 01:13am
